We are live on ! Find out more
TRVI icon

Trevi Therapeutics
TRVI

17 hedge funds and large institutions have $10.3M invested in Trevi Therapeutics in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

6% less funds holding

Funds holding: 18 → 17 (-1)

6.68% less ownership

Funds ownership: 57.63% → 50.95% (-6.7%)

41% less capital invested

Capital invested by funds: $17.4M → $10.3M (-$7.14M)

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.59M
2
Renaissance Technologies
Renaissance Technologies
New York
+$285K
3
Millennium Management
Millennium Management
New York
+$128K
4
BCM
Bridgeway Capital Management
Texas
+$42.4K
5
Citadel Advisors
Citadel Advisors
Florida
+$33.3K

Top Sellers

Rank Fund Capital Flow
1
OFM
Omega Fund Management
Massachusetts
-$1.77M
2
WA
WealthTrust Axiom
Pennsylvania
-$8.4K
3
UBS Group
UBS Group
Switzerland
-$7K

TRVI Hedge Fund Activity: Q4 2021 in Review

17 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q4 2021, worth a combined $10.3M — down 41% from $17.4M a quarter earlier.

Fund positioning in TRVI was balanced in Q4 2021: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.59M. The largest seller was Omega Fund Management, exiting entirely with an estimated $1.77M sold.

  • 17 institutional investors held Trevi Therapeutics (TRVI) as of Q4 2021, down from 18 in Q3 2021.
  • Funds reported $10.3M of Trevi Therapeutics stock for Q4 2021, down 41% quarter-over-quarter.
  • 4 funds opened new Trevi Therapeutics positions in Q4 2021 and 4 closed out, a net change of 0 holders.
  • The largest Trevi Therapeutics buyer in Q4 2021 was Armistice Capital, an estimated $1.59M added.
  • The largest Trevi Therapeutics seller in Q4 2021 was Omega Fund Management, an estimated $1.77M sold.

Based on aggregated 13F filings for Q4 2021.